KEGG   DRUG: Insulin
Entry
D00085                      Drug                                   
Name
Insulin (JAN/USP)
Sequence
(A chain) Gly Ile Val Glu Gln Cys Cys Thr Ser Ile Cys Ser Leu Tyr
Gln Leu Glu Asn Tyr Cys Asn
(B chain) Phe Val Asn Gln His Leu Cys Gly Ser His Leu Val Glu Ala
Leu Tyr Leu Val Cys Gly Glu Arg Gly Phe Phe Tyr Thr Pro Lys Thr
(Disulfide bridge: A6-A11, A7-B7, A20-B19)
  Type
Peptide
Class
Antidiabetic agent
 DG01636  Insulin preparation
Remark
Same as: C00723
Efficacy
Antidiabetic, Insulin receptor agonist
Comment
Pancreas hormone
Target
INSR (CD220) [HSA:3643] [KO:K04527]
  Pathway
hsa04910  Insulin signaling pathway
Interaction
Structure map
map07051  Antidiabetics
Brite
Drug groups [BR:br08330]
 Antidiabetic agent
  DG01636  Insulin preparation
   D00085  Insulin
Target-based classification of drugs [BR:br08310]
 Protein kinases
  Receptor tyrosine kinases (RTK)
   INSR family
    INSR (CD220)
     D00085  Insulin (JAN/USP)
Other DBs
CAS: 9004-10-8
PubChem: 7847153
ChEBI: 5931
NIKKAJI: J2.730.443E
LinkDB

» Japanese version   » Back

KEGG   DRUG: Insulin human
Entry
D03230                      Drug                                   
Name
Insulin human (USP/INN);
Insulin human (genetical recombination) (JP18);
Insulin human (biosynthesis) (JAN);
Insulin human (synthesis) (JAN);
Humulin (TN)
Product
HUMULIN (Eli Lilly and Company), MYXREDLIN (Baxter Healthcare Corporation)
Formula
C257H383N65O77S6
Exact mass
5803.6376
Mol weight
5807.5702
Sequence
(A chain) Gly Ile Val Glu Gln Cys Cys Thr Ser Ile Cys Ser Leu Tyr
Gln Leu Glu Asn Tyr Cys Asn
(B chain) Phe Val Asn Gln His Leu Cys Gly Ser His Leu Val Glu Ala
Leu Tyr Leu Val Cys Gly Glu Arg Gly Phe Phe Tyr Thr Pro Lys Thr
(Disulfide bridge: A6-A11, A7-B7, A20-B19)
  Type
Peptide
Class
Antidiabetic agent
 DG01636  Insulin preparation
  DG01802  Human insulin
Metabolizing enzyme inducer
 DG01637  CYP1A2 inducer
Remark
Therapeutic category: 2492
ATC code: A10AB01 A10AC01 A10AD01 A10AE01 A10AF01
Product: D03230<JP/US>
Efficacy
Antidiabetic, Insulin receptor agonist
  Disease
Diabetes mellitus [DS:H00408 H00409]
Target
INSR (CD220) [HSA:3643] [KO:K04527]
  Pathway
hsa04910  Insulin signaling pathway
hsa04930  Type II diabetes mellitus
Interaction
CYP induction: CYP1A2 [HSA:1544]
Structure map
map07051  Antidiabetics
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 A ALIMENTARY TRACT AND METABOLISM
  A10 DRUGS USED IN DIABETES
   A10A INSULINS AND ANALOGUES
    A10AB Insulins and analogues for injection, fast-acting
     A10AB01 Insulin (human)
      D03230  Insulin human (USP/INN) <JP/US>
    A10AC Insulins and analogues for injection, intermediate-acting
     A10AC01 Insulin (human)
      D03230  Insulin human (USP/INN) <JP/US>
    A10AD Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting
     A10AD01 Insulin (human)
      D03230  Insulin human (USP/INN) <JP/US>
    A10AE Insulins and analogues for injection, long-acting
     A10AE01 Insulin (human)
      D03230  Insulin human (USP/INN) <JP/US>
    A10AF Insulins and analogues for inhalation
     A10AF01 Insulin (human)
      D03230  Insulin human (USP/INN) <JP/US>
USP drug classification [BR:br08302]
 Blood Glucose Regulators
  Insulins
   Insulin, Rapid-acting
    Insulin Human
     D03230  Insulin human (USP/INN)
Therapeutic category of drugs in Japan [BR:br08301]
 2  Agents affecting individual organs
  24  Hormones
   249  Miscellaneous
    2492  Pancreatic hormones
     D03230  Insulin human (USP/INN); Insulin human (genetical recombination) (JP18); Insulin human (biosynthesis) (JAN); Insulin human (synthesis) (JAN)
Drug groups [BR:br08330]
 Antidiabetic agent
  DG01636  Insulin preparation
   DG01802  Human insulin
    D03230  Insulin human
 Metabolizing enzyme inducer
  DG01637  CYP1A2 inducer
   D03230  Insulin human
Drug classes [BR:br08332]
 Antidiabetic agent
  DG01636  Insulin preparation
   D03230  Insulin human
Target-based classification of drugs [BR:br08310]
 Protein kinases
  Receptor tyrosine kinases (RTK)
   INSR family
    INSR (CD220)
     D03230  Insulin human (USP/INN) <JP/US>
Drugs listed in the Japanese Pharmacopoeia [BR:br08311]
 Chemicals
  D03230  Insulin human (genetical recombination)
  D03230  Insulin human (genetical recombination) injection
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D03230
Drug metabolizing enzymes and transporters [br08309.html]
 Drug metabolizing enzymes
  D03230
Other DBs
CAS: 11061-68-0
PubChem: 17397383
LinkDB

» Japanese version   » Back

KEGG   DRUG: Insulin glargine
Entry
D03250                      Drug                                   
Name
Insulin glargine (USAN/INN);
Insulin glargine (genetical recombination) (JP18);
Insulin glargine (genetical recombination) [Insulin glargin biosimilar 1] (JAN);
Insulin glargine (genetical recombination) [Insulin glargin biosimilar 2] (JAN);
Lantus (TN)
Product
BASAGLAR (Eli Lilly and Company), INSULIN GLARGINE (A-S Medication Solutions), INSULIN GLARGINE (Mylan Specialty L.P.), INSULIN GLARGINE (Sanofi-Aventis U.S. LLC), INSULIN GLARGINE (Winthrop U.S.), INSULIN GLARGINE (Winthrop U.S.), INSULIN GLARGINE (sanofi-aventis U.S. LLC), INSULIN GLARGINE (sanofi-aventis U.S. LLC), INSULIN GLARGINE SOLOSTAR (A-S Medication Solutions), REZVOGLAR (Eli Lilly and Company), SEMGLEE (Mylan Specialty L.P.), TOUJEO (A-S Medication Solutions), TOUJEO MAX (A-S Medication Solutions)
Formula
C267H404N72O78S6
Exact mass
6058.8184
Mol weight
6062.8903
Sequence
(A chain) Gly Ile Val Glu Gln Cys Cys Thr Ser Ile Cys Ser Leu Tyr
Gln Leu Glu Asn Tyr Cys Gly
(B chain) Phe Val Asn Gln His Leu Cys Gly Ser His Leu Val Glu Ala
Leu Tyr Leu Val Cys Gly Glu Arg Gly Phe Phe Tyr Thr Pro Lys Thr
Arg Arg
(Disulfide bridge: A6-A11, A7-B7, A20-B19)
  Type
Peptide
Class
Antidiabetic agent
 DG01636  Insulin preparation
  DG01797  Insulin analog, long-acting
Metabolizing enzyme inducer
 DG01637  CYP1A2 inducer
Remark
Therapeutic category: 2492
ATC code: A10AE04
Product: D03250<JP/US>
Product (mixture): D11034<JP/US>
Efficacy
Antidiabetic, Insulin receptor agonist
  Disease
Diabetes mellitus [DS:H00408 H00409]
Target
INSR (CD220) [HSA:3643] [KO:K04527]
  Pathway
hsa04910  Insulin signaling pathway
hsa04930  Type II diabetes mellitus
Interaction
CYP induction: CYP1A2 [HSA:1544]
Structure map
map07051  Antidiabetics
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 A ALIMENTARY TRACT AND METABOLISM
  A10 DRUGS USED IN DIABETES
   A10A INSULINS AND ANALOGUES
    A10AE Insulins and analogues for injection, long-acting
     A10AE04 Insulin glargine
      D03250  Insulin glargine (USAN/INN) <JP/US>
USP drug classification [BR:br08302]
 Blood Glucose Regulators
  Insulins
   Insulin, Long-acting
    Insulin Glargine
     D03250  Insulin glargine (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
 2  Agents affecting individual organs
  24  Hormones
   249  Miscellaneous
    2492  Pancreatic hormones
     D03250  Insulin glargine (USAN/INN); Insulin glargine (genetical recombination) (JP18); Insulin glargine (genetical recombination) [Insulin glargin biosimilar 1] (JAN); Insulin glargine (genetical recombination) [Insulin glargin biosimilar 2] (JAN)
Drug groups [BR:br08330]
 Antidiabetic agent
  DG01636  Insulin preparation
   DG01797  Insulin analog, long-acting
    D03250  Insulin glargine
 Metabolizing enzyme inducer
  DG01637  CYP1A2 inducer
   D03250  Insulin glargine
Drug classes [BR:br08332]
 Antidiabetic agent
  DG01636  Insulin preparation
   D03250  Insulin glargine
Target-based classification of drugs [BR:br08310]
 Protein kinases
  Receptor tyrosine kinases (RTK)
   INSR family
    INSR (CD220)
     D03250  Insulin glargine (USAN/INN) <JP/US>
Drugs listed in the Japanese Pharmacopoeia [BR:br08311]
 Chemicals
  D03250  Insulin glargine (genetical recombination)
  D03250  Insulin glargine (genetical recombination) injection
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D03250
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D03250
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D03250
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D03250
Drug metabolizing enzymes and transporters [br08309.html]
 Drug metabolizing enzymes
  D03250
Other DBs
CAS: 160337-95-1
PubChem: 17397403
NIKKAJI: J2.173.686D
LinkDB

» Japanese version   » Back

KEGG   DRUG: Insulin aspart
Entry
D04475                      Drug                                   
Name
Insulin aspart (USP/INN);
Insulin aspart (genetical recombination) (JP18);
Insulin aspart (genetical recombination) [Insulin aspart biosimilar 1] (JAN);
Insulin X 14;
NovoRapid (TN);
Novolog (TN)
Product
FIASP (Novo Nordisk), INSULIN ASPART (Novo Nordisk Pharma), INSULIN ASPART (REMEDYREPACK), INSULIN ASPART PROTAMINE AND INSULIN ASPART (Novo Nordisk Pharma), INSULIN ASPART PROTAMINE AND INSULIN ASPART (REMEDYREPACK), NOVOLOG (A-S Medication Solutions), NOVOLOG (A-S Medication Solutions), NOVOLOG MIX 70/30 (A-S Medication Solutions), NOVOLOG MIX 70/30 (Novo Nordisk), NOVOLOG MIX 70/30 (REMEDYREPACK), WATER INJECTION (Novo Nordisk)
Formula
C256H381N65O79S6
Exact mass
5821.6118
Mol weight
5825.5424
Sequence
(A chain) Gly Ile Val Glu Gln Cys Cys Thr Ser Ile Cys Ser Leu Tyr
Gln Leu Glu Asn Tyr Cys Asn
(B chain) Phe Val Asn Gln His Leu Cys Gly Ser His Leu Val Glu Ala
Leu Tyr Leu Val Cys Gly Glu Arg Gly Phe Phe Tyr Thr Asp Lys Thr
(Disulfide bridge: A6-A11, A7-B7, A20-B19)
  Type
Peptide
Class
Antidiabetic agent
 DG01636  Insulin preparation
  DG01796  Insulin analog, fast-acting
Metabolizing enzyme inducer
 DG01637  CYP1A2 inducer
Remark
Therapeutic category: 2492
ATC code: A10AB05 A10AD05
Product: D04475<JP/US>
Product (mixture): D10570<JP>
Efficacy
Antidiabetic, Insulin receptor agonist
  Disease
Diabetes mellitus [DS:H00408 H00409]
Comment
insulin analog
Target
INSR (CD220) [HSA:3643] [KO:K04527]
  Pathway
hsa04910  Insulin signaling pathway
hsa04930  Type II diabetes mellitus
Interaction
CYP induction: CYP1A2 [HSA:1544]
Structure map
map07051  Antidiabetics
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 A ALIMENTARY TRACT AND METABOLISM
  A10 DRUGS USED IN DIABETES
   A10A INSULINS AND ANALOGUES
    A10AB Insulins and analogues for injection, fast-acting
     A10AB05 Insulin aspart
      D04475  Insulin aspart (USP/INN) <JP/US>
    A10AD Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting
     A10AD05 Insulin aspart
      D04475  Insulin aspart (USP/INN) <JP/US>
USP drug classification [BR:br08302]
 Blood Glucose Regulators
  Insulins
   Insulin, Rapid-acting
    Insulin Aspart
     D04475  Insulin aspart (USP/INN)
Therapeutic category of drugs in Japan [BR:br08301]
 2  Agents affecting individual organs
  24  Hormones
   249  Miscellaneous
    2492  Pancreatic hormones
     D04475  Insulin aspart (USP/INN); Insulin aspart (genetical recombination) (JP18); Insulin aspart (genetical recombination) [Insulin aspart biosimilar 1] (JAN)
Drug groups [BR:br08330]
 Antidiabetic agent
  DG01636  Insulin preparation
   DG01796  Insulin analog, fast-acting
    D04475  Insulin aspart
 Metabolizing enzyme inducer
  DG01637  CYP1A2 inducer
   D04475  Insulin aspart
Drug classes [BR:br08332]
 Antidiabetic agent
  DG01636  Insulin preparation
   D04475  Insulin aspart
Target-based classification of drugs [BR:br08310]
 Protein kinases
  Receptor tyrosine kinases (RTK)
   INSR family
    INSR (CD220)
     D04475  Insulin aspart (USP/INN) <JP/US>
Drugs listed in the Japanese Pharmacopoeia [BR:br08311]
 Chemicals
  D04475  Insulin aspart (genetical recombination)
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D04475
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D04475
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D04475
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D04475
Drug metabolizing enzymes and transporters [br08309.html]
 Drug metabolizing enzymes
  D04475
Other DBs
CAS: 116094-23-6
PubChem: 17398122
LinkDB

» Japanese version   » Back

KEGG   DRUG: Insulin lispro
Entry
D04477                      Drug                                   
Name
Insulin lispro (USP/INN);
Insulin lispro (genetical recombination) (JAN);
Insulin lispro (genetical recombination) [Insulin lispro Biosimilar 1] (JAN);
Insulin lispro-aabc;
Humalog (TN);
Lyumjev (TN)
Product
ADMELOG (Sanofi-Aventis U.S. LLC), HUMALOG (Eli Lilly and Company), HUMALOG (Eli Lilly and Company), HUMALOG (Eli Lilly and Company), INSULIN LISPRO (Eli Lilly and Company), INSULIN LISPRO PROTAMINE AND INSULIN LISPRO INJECTABLE SUSPENSION (Eli Lilly and Company), LYUMJEV (Eli Lilly and Company)
Formula
C257H383N65O77S6
Exact mass
5803.6376
Mol weight
5807.5702
Sequence
(A chain) Gly Ile Val Glu Gln Cys Cys Thr Ser Ile Cys Ser Leu Tyr
Gln Leu Glu Asn Tyr Cys Asn
(B chain) Phe Val Asn Gln His Leu Cys Gly Ser His Leu Val Glu Ala
Leu Tyr Leu Val Cys Gly Glu Arg Gly Phe Phe Tyr Thr Lys Pro Thr
(Disulfide bridge: A6-A11, A7-B7, A20-B19)
  Type
Peptide
Class
Antidiabetic agent
 DG01636  Insulin preparation
  DG01796  Insulin analog, fast-acting
Metabolizing enzyme inducer
 DG01637  CYP1A2 inducer
Remark
Therapeutic category: 2492
ATC code: A10AB04 A10AC04 A10AD04
Product: D04477<JP/US>
Efficacy
Antidiabetic, Insulin receptor agonist
  Disease
Diabetes mellitus [DS:H00408 H00409]
Comment
Insulin analog
Target
INSR (CD220) [HSA:3643] [KO:K04527]
  Pathway
hsa04910  Insulin signaling pathway
hsa04930  Type II diabetes mellitus
Interaction
CYP induction: CYP1A2 [HSA:1544]
Structure map
map07051  Antidiabetics
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 A ALIMENTARY TRACT AND METABOLISM
  A10 DRUGS USED IN DIABETES
   A10A INSULINS AND ANALOGUES
    A10AB Insulins and analogues for injection, fast-acting
     A10AB04 Insulin lispro
      D04477  Insulin lispro (USP/INN) <JP/US>
    A10AC Insulins and analogues for injection, intermediate-acting
     A10AC04 Insulin lispro
      D04477  Insulin lispro (USP/INN) <JP/US>
    A10AD Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting
     A10AD04 Insulin lispro
      D04477  Insulin lispro (USP/INN) <JP/US>
USP drug classification [BR:br08302]
 Blood Glucose Regulators
  Insulins
   Insulin, Rapid-acting
    Insulin Lispro
     D04477  Insulin lispro (USP/INN)
Therapeutic category of drugs in Japan [BR:br08301]
 2  Agents affecting individual organs
  24  Hormones
   249  Miscellaneous
    2492  Pancreatic hormones
     D04477  Insulin lispro (USP/INN); Insulin lispro (genetical recombination) (JAN); Insulin lispro (genetical recombination) [Insulin lispro Biosimilar 1] (JAN)
Drug groups [BR:br08330]
 Antidiabetic agent
  DG01636  Insulin preparation
   DG01796  Insulin analog, fast-acting
    D04477  Insulin lispro
 Metabolizing enzyme inducer
  DG01637  CYP1A2 inducer
   D04477  Insulin lispro
Drug classes [BR:br08332]
 Antidiabetic agent
  DG01636  Insulin preparation
   D04477  Insulin lispro
Target-based classification of drugs [BR:br08310]
 Protein kinases
  Receptor tyrosine kinases (RTK)
   INSR family
    INSR (CD220)
     D04477  Insulin lispro (USP/INN) <JP/US>
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D04477
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D04477
Drug metabolizing enzymes and transporters [br08309.html]
 Drug metabolizing enzymes
  D04477
Other DBs
CAS: 133107-64-9
PubChem: 17398123
LinkDB

» Japanese version   » Back

KEGG   DRUG: Insulin detemir
Entry
D04539                      Drug                                   
Name
Insulin detemir (USAN/INN);
Insulin detemir (genetical recombination) (JAN);
Levemir (TN)
Product
LEVEMIR (A-S Medication Solutions), LEVEMIR (Novo Nordisk)
Formula
C267H402N64O76S6
Exact mass
5912.7883
Mol weight
5916.822
Sequence
(A chain) Gly Ile Val Glu Gln Cys Cys Thr Ser Ile Cys Ser Leu Tyr
Gln Leu Glu Asn Tyr Cys Asn
(B chain) Phe Val Asn Gln His Leu Cys Gly Ser His Leu Val Glu Ala
Leu Tyr Leu Val Cys Gly Glu Arg Gly Phe Phe Tyr Thr Pro
Lys-C14H27O
(Disulfide bridge: A6-A11, A7-B7, A20-B19)
  Type
Peptide
Class
Antidiabetic agent
 DG01636  Insulin preparation
  DG01797  Insulin analog, long-acting
Metabolizing enzyme inducer
 DG01637  CYP1A2 inducer
Remark
Therapeutic category: 2492
ATC code: A10AE05
Product: D04539<JP/US>
Efficacy
Antidiabetic, Insulin receptor agonist
  Disease
Diabetes mellitus [DS:H00408 H00409]
Comment
Insulin analog
Target
INSR (CD220) [HSA:3643] [KO:K04527]
  Pathway
hsa04910  Insulin signaling pathway
hsa04930  Type II diabetes mellitus
Interaction
CYP induction: CYP1A2 [HSA:1544]
Structure map
map07051  Antidiabetics
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 A ALIMENTARY TRACT AND METABOLISM
  A10 DRUGS USED IN DIABETES
   A10A INSULINS AND ANALOGUES
    A10AE Insulins and analogues for injection, long-acting
     A10AE05 Insulin detemir
      D04539  Insulin detemir (USAN/INN) <JP/US>
USP drug classification [BR:br08302]
 Blood Glucose Regulators
  Insulins
   Insulin, Long-acting
    Insulin Detemir
     D04539  Insulin detemir (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
 2  Agents affecting individual organs
  24  Hormones
   249  Miscellaneous
    2492  Pancreatic hormones
     D04539  Insulin detemir (USAN/INN); Insulin detemir (genetical recombination) (JAN)
Drug groups [BR:br08330]
 Antidiabetic agent
  DG01636  Insulin preparation
   DG01797  Insulin analog, long-acting
    D04539  Insulin detemir
 Metabolizing enzyme inducer
  DG01637  CYP1A2 inducer
   D04539  Insulin detemir
Drug classes [BR:br08332]
 Antidiabetic agent
  DG01636  Insulin preparation
   D04539  Insulin detemir
Target-based classification of drugs [BR:br08310]
 Protein kinases
  Receptor tyrosine kinases (RTK)
   INSR family
    INSR (CD220)
     D04539  Insulin detemir (USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D04539
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D04539
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D04539
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D04539
Drug metabolizing enzymes and transporters [br08309.html]
 Drug metabolizing enzymes
  D04539
Other DBs
CAS: 169148-63-4
PubChem: 17398128
NIKKAJI: J2.337.674A
LinkDB

» Japanese version   » Back

KEGG   DRUG: Insulin glulisine
Entry
D04540                      Drug                                   
Name
Insulin glulisine (USAN/INN);
Insulin glulisine (genetical recombination) (JAN);
Apidra (TN)
Product
INSULIN GLULISINE (sanofi-aventis U.S. LLC)
Formula
C258H384N64O78S6
Exact mass
5818.6373
Mol weight
5822.5816
Sequence
(A chain) Gly Ile Val Glu Gln Cys Cys Thr Ser Ile Cys Ser Leu Tyr
Gln Leu Glu Asn Tyr Cys Asn
(B chain) Phe Val Lys Gln His Leu Cys Gly Ser His Leu Val Glu Ala
Leu Tyr Leu Val Cys Gly Glu Arg Gly Phe Phe Tyr Thr Pro Glu Thr
(Disulfide bridge: A6-A11, A7-B7, A20-B19)
  Type
Peptide
Class
Antidiabetic agent
 DG01636  Insulin preparation
  DG01796  Insulin analog, fast-acting
Metabolizing enzyme inducer
 DG01637  CYP1A2 inducer
Remark
Therapeutic category: 2492
ATC code: A10AB06
Product: D04540<JP/US>
Efficacy
Antidiabetic, Insulin receptor agonist
  Disease
Diabetes mellitus [DS:H00408 H00409]
Comment
Insulin analog
Treatment of type 1 and type 2 diabetes
Target
INSR (CD220) [HSA:3643] [KO:K04527]
  Pathway
hsa04910  Insulin signaling pathway
hsa04930  Type II diabetes mellitus
Interaction
CYP induction: CYP1A2 [HSA:1544]
Structure map
map07051  Antidiabetics
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 A ALIMENTARY TRACT AND METABOLISM
  A10 DRUGS USED IN DIABETES
   A10A INSULINS AND ANALOGUES
    A10AB Insulins and analogues for injection, fast-acting
     A10AB06 Insulin glulisine
      D04540  Insulin glulisine (USAN/INN) <JP/US>
USP drug classification [BR:br08302]
 Blood Glucose Regulators
  Insulins
   Insulin, Rapid-acting
    Insulin Glulisine, Human
     D04540  Insulin glulisine (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
 2  Agents affecting individual organs
  24  Hormones
   249  Miscellaneous
    2492  Pancreatic hormones
     D04540  Insulin glulisine (USAN/INN); Insulin glulisine (genetical recombination) (JAN)
Drug groups [BR:br08330]
 Antidiabetic agent
  DG01636  Insulin preparation
   DG01796  Insulin analog, fast-acting
    D04540  Insulin glulisine
 Metabolizing enzyme inducer
  DG01637  CYP1A2 inducer
   D04540  Insulin glulisine
Drug classes [BR:br08332]
 Antidiabetic agent
  DG01636  Insulin preparation
   D04540  Insulin glulisine
Target-based classification of drugs [BR:br08310]
 Protein kinases
  Receptor tyrosine kinases (RTK)
   INSR family
    INSR (CD220)
     D04540  Insulin glulisine (USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D04540
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D04540
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D04540
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D04540
Drug metabolizing enzymes and transporters [br08309.html]
 Drug metabolizing enzymes
  D04540
Other DBs
CAS: 207748-29-6
PubChem: 47206386
LinkDB

» Japanese version   » Back

KEGG   DRUG: Insulin human, isophane
Entry
D04541            Mixture   Drug                                   
Name
Insulin human, isophane (USP)
Component
Insulin human [DR:D03230], Isophane insulin [DR:D04547]
Class
Antidiabetic agent
 DG01636  Insulin preparation
  DG01802  Human insulin
Efficacy
Antidiabetic, Insulin receptor agonist
Comment
Component of Humulin 70/30 (TN)
Target
INSR (CD220) [HSA:3643] [KO:K04527]
  Pathway
hsa04910  Insulin signaling pathway
Interaction
Structure map
map07051  Antidiabetics
Brite
Drug groups [BR:br08330]
 Antidiabetic agent
  DG01636  Insulin preparation
   DG01802  Human insulin
    D04541  Insulin human, isophane
Target-based classification of drugs [BR:br08310]
 Protein kinases
  Receptor tyrosine kinases (RTK)
   INSR family
    INSR (CD220)
     D04541  Insulin human, isophane (USP)
Other DBs
PubChem: 47206387
LinkDB

» Japanese version   » Back

KEGG   DRUG: Insulin, isophane
Entry
D04547                      Drug                                   
Name
Insulin, isophane (USP);
Isophane insulin human (genetical recombination) injectable aqueous suspension (JP18);
Isophane insulin (aqueous suspension) (JAN);
Humalog PEN (TN)
Class
Antidiabetic agent
 DG01636  Insulin preparation
  DG01802  Human insulin
Metabolizing enzyme inducer
 DG01637  CYP1A2 inducer
Remark
Product: D04547<JP>
Efficacy
Antidiabetic, Insulin receptor agonist
Target
INSR (CD220) [HSA:3643] [KO:K04527]
  Pathway
hsa04910  Insulin signaling pathway
Interaction
CYP induction: CYP1A2 [HSA:1544]
Structure map
map07051  Antidiabetics
Brite
Drug groups [BR:br08330]
 Antidiabetic agent
  DG01636  Insulin preparation
   DG01802  Human insulin
    D04547  Insulin, isophane
 Metabolizing enzyme inducer
  DG01637  CYP1A2 inducer
   D04547  Insulin, isophane
Drug classes [BR:br08332]
 Antidiabetic agent
  DG01636  Insulin preparation
   D04547  Insulin, isophane
Target-based classification of drugs [BR:br08310]
 Protein kinases
  Receptor tyrosine kinases (RTK)
   INSR family
    INSR (CD220)
     D04547  Insulin, isophane (USP) <JP>
Drugs listed in the Japanese Pharmacopoeia [BR:br08311]
 Chemicals
  D04547  Isophane insulin human (genetical recombination) injectable aqueous suspension
Drug metabolizing enzymes and transporters [br08309.html]
 Drug metabolizing enzymes
  D04547
Other DBs
CAS: 53027-39-7
PubChem: 17398129
LinkDB

» Japanese version   » Back

KEGG   DRUG: Insulin degludec
Entry
D09727                      Drug                                   
Name
Insulin degludec (USAN/INN);
Insulin degludec (genetical recombination) (JAN);
Tresiba (TN)
Product
INSULIN DEGLUDEC (Novo Nordisk Pharma), TRESIBA (A-S Medication Solutions), TRESIBA (Novo Nordisk)
Formula
C274H411N65O81S6
Exact mass
6099.8364
Mol weight
6103.972
Sequence
(A chain) Phe Val Asn Gln His Leu Cys Gly Ser His Leu Val Glu Ala
Leu Tyr Leu Val Cys Gly Glu Arg Gly Phe Phe Tyr Thr Pro Lys
(Amide bridge: 29-C)
(B chain) Gly Ile Val Glu Gln Cys Cys Thr Ser Ile Cys Ser Leu Tyr
Gln Leu Glu Asn Tyr Cys Asn
(Disulfide bridge: 6-11, A7-B7, A19-B20)
(C chain)
  Type
Peptide
Class
Antidiabetic agent
 DG01636  Insulin preparation
  DG01797  Insulin analog, long-acting
Remark
Therapeutic category: 2492
ATC code: A10AE06
Product: D09727<JP/US>
Product (mixture): D10570<JP> D11567<JP/US>
Efficacy
Antidiabetic, Insulin receptor agonist
  Disease
Diabetes mellitus [DS:H00408 H00409]
Comment
Insulin analog
Treatment of diabetes
Target
INSR (CD220) [HSA:3643] [KO:K04527]
  Pathway
hsa04910  Insulin signaling pathway
hsa04930  Type II diabetes mellitus
Interaction
Structure map
map07051  Antidiabetics
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 A ALIMENTARY TRACT AND METABOLISM
  A10 DRUGS USED IN DIABETES
   A10A INSULINS AND ANALOGUES
    A10AE Insulins and analogues for injection, long-acting
     A10AE06 Insulin degludec
      D09727  Insulin degludec (USAN/INN) <JP/US>
USP drug classification [BR:br08302]
 Blood Glucose Regulators
  Insulins
   Insulin, Long-acting
    Insulin Degludec
     D09727  Insulin degludec (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
 2  Agents affecting individual organs
  24  Hormones
   249  Miscellaneous
    2492  Pancreatic hormones
     D09727  Insulin degludec (USAN/INN); Insulin degludec (genetical recombination) (JAN)
Drug groups [BR:br08330]
 Antidiabetic agent
  DG01636  Insulin preparation
   DG01797  Insulin analog, long-acting
    D09727  Insulin degludec
Drug classes [BR:br08332]
 Antidiabetic agent
  DG01636  Insulin preparation
   D09727  Insulin degludec
Target-based classification of drugs [BR:br08310]
 Protein kinases
  Receptor tyrosine kinases (RTK)
   INSR family
    INSR (CD220)
     D09727  Insulin degludec (USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D09727
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D09727
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D09727
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D09727
Other DBs
CAS: 844439-96-9
PubChem: 124490467
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system